Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Lixte Biotechnology Holdings ( (LIXT) ) has shared an announcement.
On December 18, 2025, Lixte Biotechnology Holdings, Inc. entered into definitive agreements for a registered direct offering of Common Stock, pre-funded warrants and common warrants, structured as 1,051,342 common or pre-funded units priced at $4.09 per unit, for expected gross proceeds of about $4.3 million, with Spartan Capital Securities acting as exclusive placement agent; the transaction was priced at-the-market under Nasdaq rules and was expected to close around December 19–23, 2025, with net proceeds earmarked for general corporate purposes and working capital. On December 16, 2025, the company also executed a termination letter with Orbit Capital Inc., ending a recently established royalty agreement tied to revenues from equipment acquired via a November 21, 2025 share exchange and mutually releasing both parties from related claims, simplifying Lixte’s capital and royalty structure as it raises new funding for its oncology development programs.
More about Lixte Biotechnology Holdings
Lixte Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical and biotechnology company focused on developing and commercializing novel cancer therapies. Its lead product candidate is LB-100, a first-in-class PP2A inhibitor aimed at enhancing the effectiveness of chemotherapies and immunotherapies, supported by a broad patent portfolio and ongoing proof-of-concept trials in ovarian clear cell carcinoma and metastatic colon cancer.
Average Trading Volume: 108,080
Technical Sentiment Signal: Hold
Current Market Cap: $27.09M
For a thorough assessment of LIXT stock, go to TipRanks’ Stock Analysis page.